SynthesisJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
Synthesis in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06358677 (A Phase II, Randomized, Double-Blind, Split-Face of Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors), which is not on this map. Cited by 396 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Randomized, Double-Blind, Split-Face of Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
Who cites it
396 citing papers in PubMed, 7 syntheses or guidelines pooled it, 551 citations in OpenAlex.
- Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- A Comprehensive Evaluation of the Effectiveness and Safety of Pembrolizumab for the Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.Current cancer drug targets · 2026Pooled it
- Efficacy and safety of bispecific antibodies versus other antitumor therapies in solid tumors: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Clinical Practice Guideline: Colorectal Cancer—Diagnosis, Treatment, Prevention, and Long-Term Follow-Up Care.Deutsches Arzteblatt international · 2025Guideline
- Surgical outcomes of simultaneous vs. staged resection in colorectal cancer with liver metastases: a systematic review and meta-analysis.BMC surgery · 2025Pooled it
- National Guidelines for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Malignancies: A Worldwide Systematic Review and Recommendations of Strength Analysis.Annals of surgical oncology · 2025Pooled it
- Cytoreductive surgery with multimodal therapies in advanced or metastatic ovarian, colorectal, and gastric cancers: a systematic review and meta-analysis of randomized trials.World journal of surgical oncology · 2025Pooled it
- Amivantamab Monotherapy in ChemorefractoryJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients.European journal of clinical investigation · 2026Trial
- Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Trial
- Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.Cancer research communications · 2025Trial
- Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.ESMO open · 2025Trial
- Encorafenib, Cetuximab, and mFOLFOX6 inThe New England journal of medicine · 2025Trial
- Real-world efficacy, safety, and treatment continuity of fruquintinib in Japanese patients with colorectal cancer: a multicentre retrospective study.ESMO gastrointestinal oncology · 2026Article
- Metastatic colorectal carcinoma to the thyroid gland: A case report and literature review.Biomedical reports · 2026Article
- The Relevance of Curative-Intent Metastasectomy in Colorectal Cancer Patients: Real-World Insights From a Certified Comprehensive Cancer Center in Germany.International journal of cancer · 2026Article
- Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.MedComm · 2026Review
- Cost of Treating Patients Who Undergo Resection of Colorectal Liver Metastases: An Australian Pilot Study.Asia-Pacific journal of clinical oncology · 2026Article
- Integrated Evaluation of Survival, Surgical Conversion, and Toxicity for Induction Therapy in Initially Unresectable Colorectal Liver Metastases: An Individual Patient Data Network Meta-analysis.Annals of surgical oncology · 2026Article
- Review
336 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 16 institutions in 3 countries.
Funding
Abstract
purposeTo develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC).
methodsASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
resultsFive systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria. RECOMMENDATIONS: Doublet chemotherapy should be offered, or triplet therapy may be offered to patients with previously untreated, initially unresectable mCRC, on the basis of included studies of chemotherapy in combination with anti-vascular endothelial growth factor antibodies. In the first-line setting, pembrolizumab is recommended for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumors; chemotherapy and anti-epidermal growth factor receptor therapy is recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.